{
    "root": "6ef83e79-8d72-4714-9642-ef42ce31f54d",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": {
        "text": "WELLBUTRIN",
        "suffix": {
            "text": "SR"
        }
    },
    "value": "20240422",
    "ingredients": [
        {
            "name": "BUPROPION HYDROCHLORIDE",
            "code": "ZG7E5POY8O"
        },
        {
            "name": "CARNAUBA WAX",
            "code": "R12CBM0EIZ"
        },
        {
            "name": "CYSTEINE HYDROCHLORIDE",
            "code": "ZT934N0X4W"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "bupropion hydrochloride",
            "code": "ZG7E5POY8O"
        }
    ],
    "indications": "wellbutrin sr ( bupropion hydrochloride ) indicated treatment major depressive disorder ( mdd ) , defined diagnostic statistical manual ( dsm ) . efficacy bupropion treatment major depressive episode established two 4-week controlled inpatient trials one 6-week controlled outpatient trial adult subjects mdd [ ( 14 ) ] . efficacy wellbutrin sr maintaining antidepressant response 44 weeks following 8 weeks acute treatment demonstrated placebo‑controlled trial [ ( 14 ) ] .",
    "contraindications": "• starting dose : 150 mg/day . ( 2.1 ) • general : increase dose gradually reduce seizure risk . ( 2.1 , 5.3 ) • 3 days , may increase dose 300 mg/day , given 150 mg twice daily interval least 8 hours . ( 2.1 ) • usual target dose : 300 mg/day 150 mg twice daily . ( 2.1 ) • maximum dose : 400 mg/day , given 200 mg twice daily , patients responding 300 mg/day . ( 2.1 ) • periodically reassess dose need maintenance treatment . ( 2.1 ) • moderate severe hepatic impairment : 100 mg daily 150 mg every day . ( 2.2 , 8.7 ) • mild hepatic impairment : consider reducing dose and/or frequency dosing . ( 2.2 , 8.7 ) • renal impairment : consider reducing dose and/or frequency . ( 2.3 , 8.6 )",
    "warningsAndPrecautions": "wellbutrin sr sustained‑release tablets , 100 mg bupropion hydrochloride , blue , round , biconvex , film‑coated tablets printed “ wellbutrin sr 100 ” bottles 60 ( ndc 0173-0947-55 ) tablets . wellbutrin sr sustained‑release tablets , 150 mg bupropion hydrochloride , purple , round , biconvex , film‑coated tablets printed “ wellbutrin sr 150 ” bottles 60 ( ndc 0173-0135-55 ) tablets . wellbutrin sr sustained‑release tablets , 200 mg bupropion hydrochloride , light pink , round , biconvex , film‑coated tablets printed “ wellbutrin sr 200 ” bottles 60 ( ndc 0173-0722-00 ) tablets . store room temperature , 20° 25°c ( 68° 77°f ) ; excursions permitted 15°c 30°c ( 59°f 86°f ) [ usp controlled room temperature ] . protect light moisture .",
    "adverseReactions": "•wellbutrin sr contraindicated patients seizure disorder . •wellbutrin sr contraindicated patients current prior diagnosis bulimia anorexia nervosa higher incidence seizures observed patients treated immediate‑release formulation bupropion [ ( 5.3 ) ] . •wellbutrin sr contraindicated patients undergoing abrupt discontinuation alcohol , benzodiazepines , barbiturates , antiepileptic drugs [ ( 5.3 ) , ( 7.3 ) ] . •the maois ( intended treat psychiatric disorders ) concomitantly wellbutrin sr within 14 days discontinuing treatment wellbutrin sr contraindicated . increased risk hypertensive wellbutrin sr used concomitantly maois . wellbutrin sr within 14 days discontinuing treatment maoi also contraindicated . starting wellbutrin sr patient treated reversible maois linezolid intravenous methylene blue contraindicated [ ( 2.4 , 2.5 ) , ( 5.4 ) , ( 7.6 ) ] . •wellbutrin sr contraindicated patients known hypersensitivity bupropion ingredients wellbutrin sr. anaphylactoid/anaphylactic stevens-johnson syndrome reported [ ( 5.8 ) ] .",
    "indications_original": "WELLBUTRIN SR (bupropion hydrochloride) is indicated for the treatment of major depressive disorder (MDD), as defined by the Diagnostic and Statistical Manual (DSM).\n                  The efficacy of bupropion in the treatment of a major depressive episode was established in two 4-week controlled inpatient trials and one 6-week controlled outpatient trial of adult subjects with MDD [see Clinical Studies (14)].\n                  The efficacy of WELLBUTRIN SR in maintaining an antidepressant response for up to 44 weeks following 8 weeks of acute treatment was demonstrated in a placebo‑controlled trial [see Clinical Studies (14)].",
    "contraindications_original": "• Starting dose: 150 mg/day. ( 2.1 ) • General: Increase dose gradually to reduce seizure risk. ( 2.1 , 5.3 ) • After 3 days, may increase the dose to 300 mg/day, given as 150 mg twice daily at an interval of at least 8 hours. ( 2.1 ) • Usual target dose: 300 mg/day as 150 mg twice daily. ( 2.1 ) • Maximum dose: 400 mg/day, given as 200 mg twice daily, for patients not responding to 300 mg/day. ( 2.1 ) • Periodically reassess the dose and need for maintenance treatment. ( 2.1 ) • Moderate to severe hepatic impairment: 100 mg daily or 150 mg every other day. ( 2.2 , 8.7 ) • Mild hepatic impairment: Consider reducing the dose and/or frequency of dosing. ( 2.2 , 8.7 ) • Renal impairment: Consider reducing the dose and/or frequency. ( 2.3 , 8.6 )",
    "warningsAndPrecautions_original": "WELLBUTRIN SR sustained‑release tablets, 100 mg of bupropion hydrochloride, are blue, round, biconvex, film‑coated tablets printed with “WELLBUTRIN SR 100” in bottles of 60 (NDC 0173-0947-55) tablets.\n                  WELLBUTRIN SR sustained‑release tablets, 150 mg of bupropion hydrochloride, are purple, round, biconvex, film‑coated tablets printed with “WELLBUTRIN SR 150” in bottles of 60 (NDC 0173-0135-55) tablets.\n                  WELLBUTRIN SR sustained‑release tablets, 200 mg of bupropion hydrochloride, are light pink, round, biconvex, film‑coated tablets printed with “WELLBUTRIN SR 200” in bottles of 60 (NDC 0173-0722-00) tablets.\n                  Store at room temperature, 20° to 25°C (68° to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature]. Protect from light and moisture.",
    "adverseReactions_original": "•WELLBUTRIN SR is contraindicated in patients with a seizure disorder.\n                     \n                        •WELLBUTRIN SR is contraindicated in patients with a current or prior diagnosis of bulimia or anorexia nervosa as a higher incidence of seizures was observed in such patients treated with the immediate‑release formulation of bupropion [see Warnings and Precautions (5.3)].\n                     \n                     \n                        •WELLBUTRIN SR is contraindicated in patients undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and antiepileptic drugs [see Warnings and Precautions (5.3), Drug Interactions (7.3)].\n                     \n                        •The use of MAOIs (intended to treat psychiatric disorders) concomitantly with WELLBUTRIN SR or within 14 days of discontinuing treatment with WELLBUTRIN SR is contraindicated. There is an increased risk of hypertensive reactions when WELLBUTRIN SR is used concomitantly with MAOIs. The use of WELLBUTRIN SR within 14 days of discontinuing treatment with an MAOI is also contraindicated. Starting WELLBUTRIN SR in a patient treated with reversible MAOIs such as linezolid or intravenous methylene blue is contraindicated [see Dosage and Administration (2.4, 2.5), Warnings and Precautions (5.4), Drug Interactions (7.6)].\n                     \n                        •WELLBUTRIN SR is contraindicated in patients with known hypersensitivity to bupropion or other ingredients of WELLBUTRIN SR. Anaphylactoid/anaphylactic reactions and Stevens-Johnson syndrome have been reported [see Warnings and Precautions (5.8)]."
}